Federal appeals court blocks telemedicine access to abortion pills nationwide

A federal appeals court has cut off telemedicine access to abortion pills across the country, a ruling that could force patients in states where abortion remains legal back into clinics, health centers and pharmacies for care they had been able to receive by mail.

The 5th U.S. Circuit Court of Appeals in New Orleans ordered the nationwide restriction on mifepristone in Louisiana v. FDA while Louisiana’s appeal moves forward, reinstating an in-person dispensing requirement that the Food and Drug Administration had lifted and then updated again through its Jan. 3, 2023 REMS change. That update had allowed mifepristone to be dispensed in person or by mail through certified prescribers and certified pharmacies.

The ruling reaches far beyond Louisiana. It affects abortion care and early miscarriage care nationwide, including in states where abortion is legally protected, because mifepristone is used both for medication abortion and for treating early pregnancy loss. Abortion rights advocates warned that the practical fallout will be immediate for people who depend on telehealth, especially rural patients, people with disabilities, those facing intimate partner violence and others who have relied on remote care to avoid long trips and delays.

The American Civil Liberties Union said more than 1 in 4 abortions in the United States now use telemedicine, underscoring how much of the current system depends on mail delivery and remote prescribing. The court’s order could force many patients to schedule extra appointments, arrange transportation, take time off work and wait longer for treatment, all while providers assess how to comply with a sudden nationwide change in access.

Mifepristone has been under legal attack for years despite repeated FDA findings that its benefits outweigh its risks and support from major medical groups that say the drug is safe and effective. The FDA first approved Mifeprex in 2000, and a generic version followed in 2019. The 2023 REMS update was a major shift because it removed the old in-person dispensing rule that had limited access to clinics, medical offices and hospitals and blocked mail delivery and retail-pharmacy dispensing.

Reproductive-rights groups said an emergency appeal to the Supreme Court of the United States is likely. For now, the 5th Circuit’s order turns a fight over one drug into a nationwide constraint on abortion access and miscarriage care, with patients, pharmacies and clinicians left to navigate the fallout.